Qatar Biobank

Qatar Biobank
Name	Qatar Biobank
Formation	2012
Type	Biobank
Headquarters	Doha, Qatar
Region served	Qatar
Leader title	Director

Qatar Biobank

Qatar Biobank is a large-scale population cohort and biospecimen repository based in Doha, Qatar, established to support biomedical research on chronic diseases and public health. It provides access to biological samples, imaging data, lifestyle questionnaires, and electronic health record linkages to investigators from academic, clinical, and industry organizations. The initiative interfaces with regional and international projects to enable genetic, epidemiological, and translational research.

Overview

Qatar Biobank operates as a national resource situated in Doha and aligned with national strategies such as the Qatar National Vision 2030 and the work of the Qatar Foundation. It collects multi-modal data including genomic, proteomic, metabolomic, radiologic, and phenotypic information to study conditions prevalent in the population, including Type 2 diabetes mellitus, Cardiovascular disease, and Obesity. The infrastructure integrates with clinical partners like Hamad Medical Corporation and academic partners including Weill Cornell Medicine-Qatar and Qatar University. International collaborations have involved institutions such as the Wellcome Trust, the National Institutes of Health, and the European Bioinformatics Institute.

History and development

The initiative was launched in the early 2010s amid regional efforts to build biomedical research capacity after consultations involving entities such as World Health Organization and the Council of Ministers (Qatar). Early planning referenced models like the UK Biobank and involved technology vendors from the United States Department of Energy research ecosystem and European partners. The first enrolment waves began in 2012 with outreach in partnership with Hamad Medical Corporation and community organizations. Subsequent phases expanded imaging capabilities with MRI and DXA scanners procured from manufacturers that serve projects including the Human Connectome Project and the International HapMap Project. Over time governance frameworks drew from international ethical guidance including the Declaration of Helsinki and recommendations from the Nuffield Council on Bioethics.

Recruitment and cohort characteristics

Enrolment criteria targeted adult citizens and long-term residents of Qatar aged 18 and above, recruited through clinics, community centers, and workplace outreach. The cohort includes participants from diverse origins present in Qatar such as families linked to the Al Thani ruling family, expatriate communities from India, Nepal, Philippines, Bangladesh, and migrants from United Kingdom and Pakistan, reflecting regional demographic patterns seen in the Gulf Cooperation Council. Baseline assessments capture age, sex, ethnicity, and family history with links to national registries like those maintained by Ministry of Public Health (Qatar) and clinical records from Hamad Medical Corporation. The dataset comprises thousands of participants with repeated follow-up assessments enabling longitudinal analyses similar in intent to cohorts like the Framingham Heart Study and the Rotterdam Study.

Data and biospecimen collection

Collected materials include whole blood, plasma, serum, urine, DNA, and aliquots for biobanking, processed in laboratories adhering to standards comparable to those of the International Organization for Standardization (ISO). Imaging modalities encompass whole-body MRI, brain MRI, DXA, and carotid ultrasound, harmonized with protocols used in the UK Biobank and Alzheimer's Disease Neuroimaging Initiative. Genotyping and sequencing efforts employ platforms from providers active in projects like the 1000 Genomes Project and Genome Aggregation Database, enabling genome-wide association studies (GWAS) and polygenic risk score development. Lifestyle and environmental exposure questionnaires draw on instruments used by the Global Burden of Disease collaborators and the World Health Survey.

Research, findings, and collaborations

Research utilizing the resource has produced investigations into the prevalence and genetic architecture of Type 2 diabetes mellitus, Hyperlipidemia, Hypertension, and rare genetic disorders found within consanguineous populations, with analytic approaches paralleling those of the International HapMap Project and large consortia such as the Global Lipids Genetics Consortium. Collaborations have included academic centers like Imperial College London, Harvard T.H. Chan School of Public Health, and industry partners engaged in translational biomarker discovery similar to initiatives from the Broad Institute and Genentech. Findings reported from analyses have informed public health priorities alongside comparative studies with cohorts such as UK Biobank, Biobank Japan Project, and the Estonian Biobank.

Governance, ethics, and data access

Governance is overseen by institutional boards with oversight from entities including the Ministry of Public Health (Qatar) and research ethics committees modeled after the Declaration of Helsinki and guidelines by the Council for International Organizations of Medical Sciences. Data access policies balance participant privacy protections with research utility, utilizing controlled-access procedures akin to those of the European Genome-phenome Archive and data-sharing agreements used by the National Institutes of Health. Ethical considerations address issues of informed consent, return of incidental findings, and benefit-sharing in contexts comparable to deliberations by the Nuffield Council on Bioethics and the Wellcome Trust. International collaborations require compliance with regulatory frameworks such as those referenced by the General Data Protection Regulation for partners in the European Union.

Category:Biobanks Category:Medical and health organisations based in Qatar